Fifty years after the discovery of the first direct genetic link to cancer, scientists are assessing the state of so-called targeted therapy.
A meeting in Philadelphia on Tuesday will mark the anniversary and examine the future of targeted therapy.
Nearly 30 treatments are on the market. A dozen or so more are under study.
But, he adds, “there is real potential to transform many cancers” into more manageable chronic diseases.
One challenge is how to expand the number of targets to attack, in part by answering what the new chief of the National Cancer Institute calls the “big questions” about what makes cancer spread, and what makes it target certain organs.